Click on a filter below to refine your search. Remove a filter to broaden your search.
For every starting age between 50 and 80 years, the projected mean event-free survival was numerically greater with finerenone versus placebo.
The greatest incidence was seen for metastatic, hematological and lung cancer; an increased risk for CVD was seen with chemotherapy.
A lower diligence level was linked to the risk for new cardiovascular disease, but a healthy lifestyle still was beneficial.